FDA
-
-
-
-
-
-
-
CervoMed completes enrollment in Phase 2 nfvPPA dementia trial
-
-
-
-
-
-
-
CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
-
-
-
-
-
-
-
CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies
-
-
-
-
-
-
-
CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
-
-
-
-
-
-
-
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies
-
-
-
-
-
-
-
CervoMed adds McKinsey veteran David Quigley to board of directors
-
-
-
-
-
-
-
CervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
-
327,948 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

